Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Laurence Gauthier-Villano"'
Publikováno v:
Annales Pharmaceutiques Françaises.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9aedbdf3a90d6f5d10c7c5d5d79a2998
https://doi.org/10.1016/j.pharma.2023.04.001
https://doi.org/10.1016/j.pharma.2023.04.001
Autor:
Pascal Rathelot, Bernard Vialettes, Laurence Gauthier-Villano, Amélie Falabregues, Pascale Pisano, Bertrand Pourroy, Marion Daul
Publikováno v:
Therapies. 70:385-402
Resume Objectifs Le bienfonde des prescriptions de molecules innovantes et onereuses hors autorisation de mise sur le marche/recommandation temporaire d’utilisation (hors AMM/RTU) necessite une evaluation pour limiter risques de sante et surcouts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0107558b0f9d46fdd8ce9562efea633f
https://doi.org/10.2515/therapie/2015008
https://doi.org/10.2515/therapie/2015008
Autor:
Raphaelle Fanciullino, Petula Vigne, Bertrand Pourroy, Amaury Guedon, Pierre Bertault Peres, Laurence Gauthier-Villano, Théau Du Repaire
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(16)
Blinatumomab is a bispecific T-cell engager antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells.[1][1] Blinatumomab was approved by the European Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c23fb3bc3b2e40f1be6b9f4624eba3cb
https://pubmed.ncbi.nlm.nih.gov/28790072
https://pubmed.ncbi.nlm.nih.gov/28790072
Autor:
P Vigne, Laurence Gauthier-Villano, Bertrand Pourroy, P Bertault-Peres, T du Repaire, A Savry
Publikováno v:
Clinical pharmacy.
Background The Food and Drug Administration has just approved blinatumomab for the treatment of paediatric patients with Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL). 1 Recommended doses in children are 5 μg/m 2 /day for 1 we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccb617c0157265866a4a6516a1ba39fc
https://doi.org/10.1136/ejhpharm-2017-000640.170
https://doi.org/10.1136/ejhpharm-2017-000640.170
Autor:
Florian Correard, Laurence Gauthier-Villano, Amandine Savry, Bertrand Pourroy, Pascale Pisano
Publikováno v:
American Journal of Health-System Pharmacy
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
American Journal of Health-System Pharmacy, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
American Journal of Health-System Pharmacy, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
Purpose The visual compatibility of a solution of defibrotide (the only drug recommended for treatment and prophylaxis of hepatic venoocclusive disease) with solutions of various drugs commonly administered in bone marrow transplant procedures was st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107ffcce4836945fa5f0e897180b21cf
https://doi.org/10.2146/ajhp130700
https://doi.org/10.2146/ajhp130700
Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?
Autor:
Bertrand Pourroy, Amandine Savry, Pascale Pisano, Magali Rocca, Laurence Gauthier-Villano, Youssef Bennis
Publikováno v:
International Journal of Clinical Pharmacy. 36:420-429
Background Nephrotoxicity is the dose-limiting side effect of cisplatin justifying the assessment of renal function for dose adjustment. Objective To determine whether appropriate dose adjustment is made in patients with renal impairment using the Co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3abbe8760bb93539be5fb56b47f32d0
https://doi.org/10.1007/s11096-013-9912-7
https://doi.org/10.1007/s11096-013-9912-7
Autor:
Amaury, Guédon, Angélique, Rome, Jean-Laurent, Deville, Michael, Besse, Ludivine, Blanchet, Amandine, Savry, Laurence, Gauthier-Villano, Pierre, Bertault-Peres, Bertrand, Pourroy
Publikováno v:
American journal of medical quality : the official journal of the American College of Medical Quality. 32(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7e14fa41f291ac5eaf1e9bcc607bc3e0
https://pubmed.ncbi.nlm.nih.gov/27565815
https://pubmed.ncbi.nlm.nih.gov/27565815
Autor:
Philippe, Garrigue, Marc, Montana, Christophe, Ventre, Amandine, Savry, Laurence, Gauthier-Villano, Pascale, Pisano, Bertrand, Pourroy
Publikováno v:
International journal of pharmaceutical compounding. 20(2)
Closed-system transfer devices enhance the drug handlers' protection against hazardous drugs exposure by prohibiting the escape of liquid or vapor from the system. PhaSeal (Becton Dickinson), a reference closed-system transfer device, includes a vial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd814a4e2c910fdc294e45252d06a620
https://pubmed.ncbi.nlm.nih.gov/27323425
https://pubmed.ncbi.nlm.nih.gov/27323425
Autor:
Bertrand Pourroy, Youssef Bennis, Florian Correard, Amandine Savry, Christophe Sauzet, Pascale Pisano, Laurence Gauthier-Villano, Marc Montana
Publikováno v:
International Journal of Pharmaceutics
International Journal of Pharmaceutics, Elsevier, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
International Journal of Pharmaceutics, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
International Journal of Pharmaceutics, Elsevier, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
International Journal of Pharmaceutics, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
Introduction Epirubicin is widely used for conventional transcatheter arterial chemoembolization (cTACE) in patients with hepatocellular-carcinoma. However, there is no data about its stability in solution at concentration higher than 2 mg/L, yet nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c17f1442567424a321ef72db4af5ee0a
https://pubmed.ncbi.nlm.nih.gov/26453779
https://pubmed.ncbi.nlm.nih.gov/26453779
Autor:
Florian Correard, Bertrand Pourroy, Pascale Pisano, Amandine Savry, Laurence Gauthier Villano, Fabien Espitallier
Publikováno v:
American Journal of Health-System Pharmacy
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
American Journal of Health-System Pharmacy, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
American Journal of Health-System Pharmacy, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
Decitabine is indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia in adults age 65 years or older who are not candidates for standard induction chemotherapy.[1][1] The decitabine powder must be aseptically recon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::419519e80adde06e7a284cdc8d3e5242
https://doi.org/10.2146/ajhp140625
https://doi.org/10.2146/ajhp140625